Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Early detection of colorectal neoplasia: application of a blood-based serological protein test on subjects undergoing population-based screening

Research output: Contribution to journalJournal articleResearchpeer-review

  1. RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Blood-based biomarkers used for colorectal cancer screening need to be developed and validated in appropriate screening populations. We aimed to develop a cancer-associated protein biomarker test for the detection of colorectal cancer in a screening population.

METHODS: Participants from the Danish Colorectal Cancer Screening Program were recruited. Blood samples were collected prior to colonoscopy. The cohort was divided into training and validation sets. We present the results of model development using the training set. Age, sex, and the serological proteins CEA, hsCRP, TIMP-1, Pepsinogen-2, HE4, CyFra21-1, Galectin-3, ferritin and B2M were used to develop a signature test to discriminate between participants with colorectal cancer versus all other findings at colonoscopy.

RESULTS: The training set included 4048 FIT-positive participants of whom 242 had a colorectal cancer. The final model for discriminating colorectal cancer versus all other findings at colonoscopy had an AUC of 0.70 (95% CI: 0.66-0.74) and included age, sex, CEA, hsCRP, HE4 and ferritin.

CONCLUSION: The performance of the biomarker signature in this FIT-positive screening population did not reflect the positive performance of biomarker signatures seen in symptomatic populations. Additional biomarkers are needed if the serological biomarkers are to be used as a frontline screening test.

Original languageEnglish
JournalBritish Journal of Cancer
Volume126
Issue number10
Pages (from-to)1387-1393
Number of pages7
ISSN0007-0920
DOIs
Publication statusPublished - Jun 2022

Bibliographical note

© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

ID: 73319744